Brief: Aclaris Therapeutics Announces Sale Of Olumiant Royalties And Milestones To Omers Life Sciences For Up To $31.5 Million
16/07/2024 21:11
July 16 (Reuters) - Aclaris Therapeutics Inc ACRS.O :
* ACLARIS THERAPEUTICS ANNOUNCES SALE OF OLUMIANT® ROYALTIES
AND
MILESTONES TO OMERS LIFE SCIENCES FOR UP TO $31.5 MILLION
* ACLARIS THERAPEUTICS INC - RECEIVES $26.5M UPFRONT PAYMENT
Source text for Eikon: ID:nGNX3LbYzF
Further company coverage: ACRS.O
((Reuters.Brief@thomsonreuters.com;))
Recent news on Aclaris Therapeutics
See all newsAclaris Therapeutics Q1 net loss widens on higher R&D spending
Brief: Aclaris Therapeutics Q1 EPS USD -0.15 Vs. IBES Estimate USD -0.16
Brief: Aclaris Therapeutics Says Positive Full Top Line Results From Phase 1A Clinical Trial Of ATI-055
Brief: Aclaris Therapeutics Completes Enrollment In Phase 2 Trial Of Bosakitug (Ati-045) In Atopic Dermatitis
Aclaris Q4 loss narrows, but misses analysts' expectations